AMYLYX PHARMACEUTICALS INC (NASDAQ: AMLX)

AMYLYX PHARMACEUTICALS INC

NASDAQ: AMLX (Amylyx Pharmaceuticals, Inc.)

Last update: 15 Feb, 1:08AM

14.12

0.05 (0.36%)

Add to watchlist

Previous Close	14.07
Open	14.00
Volume	611,350
Avg. Volume (3M)	1,516,440
Market Cap	1,550,652,288

Price / Sales	0.660
Price / Book	4.94

52 Weeks Range	2.60 (-81%) — 17.49 (23%)
Earnings Date	6 Nov 2025

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - Specialty & Generic (US)	Mixed	Mixed
	Drug Manufacturers - Specialty & Generic (Global)	Mixed	Mixed
Stock	Amylyx Pharmaceuticals, Inc.	Bullish	Bullish

AIStockmoo Score

0.5

Analyst Consensus	4.0
Insider Activity	1.5
Price Volatility	-3.5
Technical Moving Averages	1.0
Technical Oscillators	-0.5
Average	0.50

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AMLX	2 B	-	-	4.94
KNSA	4 B	-	61.55	6.20
BCRX	2 B	-	6.79	56.59
HROW	2 B	-	-	26.22
ALVO	1 B	-	16.48	-
ETON	462 M	-	-	19.37

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Investment Style	Small Growth
% Held by Insiders	9.54%
% Held by Institutions	85.89%

52 Weeks Range	2.60 (-81%) — 17.49 (23%)
Price Target Range	19.00 (34%) — 34.00 (140%)
High	34.00 (HC Wainwright & Co., 140.79%)	Buy
Median	21.00 (48.73%)
Low	19.00 (B of A Securities, 34.56%)	Buy
Average	24.67 (74.72%)
Total	3 Buy
Avg. Price @ Call	14.39

Firm	Date	Target Price	Call	Price @ Call
HC Wainwright & Co.	04 Mar 2026	34.00 (140.79%)	Buy	15.05
HC Wainwright & Co.	10 Feb 2026	28.00 (98.30%)	Buy	14.89
Stifel	03 Mar 2026	21.00 (48.73%)	Buy	14.11
B of A Securities	20 Feb 2026	19.00 (34.56%)	Buy	14.01

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
BEDROSIAN CAMILLE L	14.10	15.30	89,529	1,254,606
COHEN JOSHUA B	14.10	15.30	219,583	3,060,982
FRATES JAMES M	14.10	15.30	88,081	1,232,451
KLEE JUSTIN B.	14.10	15.30	219,583	3,060,982
MAZZARIELLO GINA	14.10	15.30	67,816	947,993
Aggregate Net Quantity				684,592
Aggregate Net Value ($)				9,557,014
Aggregate Avg. Buy ($)				14.10
Aggregate Avg. Sell ($)				15.30
Insider Range ($)				14.10 (-0%) — 15.30 (8%)

Name	Holder	Date	Type	Quantity	Price	Value ($)
BEDROSIAN CAMILLE L	Officer	05 Mar 2026	Acquired (+)	95,990	14.10	1,353,459
KLEE JUSTIN B.	Officer	05 Mar 2026	Acquired (+)	248,865	14.10	3,508,997
COHEN JOSHUA B	Officer	05 Mar 2026	Acquired (+)	248,865	14.10	3,508,997
MAZZARIELLO GINA	Officer	05 Mar 2026	Acquired (+)	74,660	14.10	1,052,706
FRATES JAMES M	Officer	05 Mar 2026	Acquired (+)	95,990	14.10	1,353,459
MAZZARIELLO GINA	Officer	02 Mar 2026	Sell (-)	6,844	15.30	104,713
BEDROSIAN CAMILLE L	Officer	02 Mar 2026	Sell (-)	6,461	15.30	98,853
FRATES JAMES M	Officer	02 Mar 2026	Sell (-)	7,909	15.30	121,008
COHEN JOSHUA B	Officer	02 Mar 2026	Sell (-)	29,282	15.30	448,015
KLEE JUSTIN B.	Officer	02 Mar 2026	Sell (-)	29,282	15.30	448,015

Date	Type	Details
08 Jan 2026	Announcement	Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	16,317.06%
Diluted EPS (TTM)	-3.10
Quarterly Revenue Growth (YOY)	-99.60%

Total Debt/Equity (MRQ)	0.69%
Current Ratio (MRQ)	12.05
Operating Cash Flow (TTM)	-206.98 M
Levered Free Cash Flow (TTM)	-182.62 M

Return on Assets (TTM)	-40.72%
Return on Equity (TTM)	-83.24%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)